Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

New Patent Granted in Japan

Published: Tuesday, October 30, 2012
Last Updated: Monday, October 29, 2012
Bookmark and Share
New patent enhances value of revolutionary new Australian blood clot diagnostic technology.

Agenix Limited has announced that Japan's Patent Office had granted a key patent covering the manufacturing process of its ThromboView® imaging agent for the detection of blood clots in humans.

Agenix Chairman and Chief Executive Officer, Nicholas Weston said, "The granting of patent protection in Japan confers further certainty and significantly increases the commercial value of the ThromboView diagnostic technology globally. In conjunction with the other patents covering the use and production of ThromboView, this new patent delivers a major commercial advantage to Agenix in one of the world's leading markets for diagnostic imaging and manufacturing.”

Japanese Patent Application Number 2003-507139 covers humanized antibodies derived from DD-3B6/22 specific for the D-dimer fragment of fibrin provides long-term protection for the company's technology through broad claims over methods of manufacture and use.

It is a major asset in the commercialization of ThromboView and establishing strategic business partnerships with global pharmaceutical and medical diagnostic companies.

ThromboView is now protected by multiple patents in the Japan, the United States, Europe, Singapore, Australia and New Zealand, with the granting of patents for China and Canada pending.

The patents provide protection for ThromboView out to 2022 with possible Hatch-Waxman term extension out to 2027.

Legislation in the EU, US and Japan grant biologics a period of 10, 12 and 6 years of data exclusivity, respectively, from the time of registration and this is likely to considerable enhance ThromboView’s protection in those markets.

Building upon and continuing to expand its international patent portfolio is fundamental to the commercial strategies of Agenix.

ThromboView will potentially provide medical professionals with a new way to accurately detect live blood clots and pulmonary embolisms in the human body without the exposure to high chest radiation and toxic chemicals used currently.

ThromboView has successfully completed two Phase II human clinical trials in the United States and there is a large body of independent clinical evidence that shows ThromboView is safe and effective.

Agenix is in discussions with potential partners in multiple geographies to partner or license the technology in order to complete its Phase III clinical study ahead of its market launch.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agenix to Acquire Diagnostic Device Technology from Tyrian
Acquisition of diagnostic device will expand Agenix’s drug and diagnostic pipeline.
Thursday, October 25, 2012
New Patent Granted in Japan Enhances Value of Diagnostic Technology
Japan's patent granted for ThromboView technology.
Monday, May 21, 2012
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Overlooked Molecules Could Revolutionise our Understanding of the Immune System
Researchers have discovered that around one third of all the epitopes displayed for scanning by the immune system are a type known as ‘spliced’ epitopes.
NIH Study Determines Key Differences between Allergic and Non-Allergic Dust Mite Proteins
Researchers at NIH have uncovered factors that lead to the development of dust mite allergy and assist in the design of better allergy therapies.
New Antibody Therapy Permanently Blocks SIV Infection
An international research team has developed an effective treatment strategy against the HIV-like Simian Immunodeficiency Virus (SIV) in rhesus macaques.
Contribution Increases by Tenfold The Mouse Mutation Resources of One Type Available
The repository provides academic researchers with unique genetic models that are unavailable commercially.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
DNA Vaccines Protect Monkeys Against Zika Virus
Two experimental Zika virus DNA vaccines developed by NIH scientists protected monkeys against Zika infection.
Rare Flu-Thwarting Mutation Discovered
Study finds protein mutation, that is encoded by influenza, causes the virus to lose any defence against the immune system.
Mapping the Human Immune System
Researchers try to harness supercomputers to create the first map of the human immune system.
Antibody Drug Conjugates May Help Personalize Radiotherapy
Biomarker-driven study shows promise in sensitizing HER2 positive tumors to radiation and chemotherapy.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos